Eli Lilly and Company announced major findings from the seven-year monarchE trial. Their CDK4/6 inhibitor, Verzenio® (abemaciclib), is the first in its class to demonstrate a statistically significant overall survival benefit for patients with HR+, HER2-, high-risk early breast cancer when added to endocrine therapy.
New data shows TECVAYLI plus DARZALEX FASPRO significantly improves survival outcomes for patients with relapsed/refractory multiple myeloma, setting the stage for a new standard of care.
Johnson & Johnson announced strong third-quarter 2025 financial results, with reported sales increasing by 6.8% to $24.0 billion. The company’s Innovative Medicine and MedTech divisions both contributed to this growth. As a result of this strong performance, Johnson & Johnson has raised its full-year 2025 sales guidance.
Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.
AstraZeneca announced a record $4.5 billion investment in its new Virginia manufacturing facility. The expansion will create 3,600 jobs and bolster the production of life-saving medicines, including next-generation ADC cancer treatments and metabolic drugs.
Johnson & Johnson announces that the U.S. FDA has approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in children weighing at least 15 kg. This approval provides a new subcutaneous treatment option for younger UC patients.
A landmark study by Ohio State scientists reveals the underlying mechanism of cancer immunotherapy failure: a fatal “proteotoxic shock” or protein quality control collapse (TexPSR) in T-cells. This newly identified stress pathway overwhelms immune cells with misfolded proteins, disabling their tumor-fighting function. Crucially, blocking the TexPSR pathway in preclinical models restored T-cell function and made immunotherapy markedly more effective, offering an entirely new target for cancer treatment development.
AbbVie has broken ground on a $70 million expansion of its Bioresearch Center in Worcester, MA, a key part of its $10 billion U.S. investment plan. The project will add new manufacturing suites and labs to increase domestic production of complex biologic medicines for immunology and oncology, creating new jobs and bringing key manufacturing capabilities from Europe to the United States.
Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial for Repatha® (evolocumab) met its primary endpoints, demonstrating a significant reduction in the risk of major adverse cardiovascular events (MACE) in high-risk individuals without a prior history of heart attack or stroke. The study, which enrolled over 12,000 patients, positions Repatha as the first and only PCSK9 inhibitor to show such a benefit in this primary prevention setting, offering a new hope for patients at high risk for cardiovascular disease.
The U.S. Food and Drug Administration (FDA) has given approval to TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in children. This groundbreaking approval makes TREMFYA® the first and only IL-23 inhibitor available for pediatric patients, offering a new ray of hope for thousands of children affected by these chronic conditions.
